Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who b...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Robert, Kersting, David, Rischpler, Christoph, Sandach, Patrick, Ferdinandus, Justin, Fendler, Wolfgang P., Rahbar, Kambiz, Weckesser, Matthias, Umutlu, Lale, Hanoun, Christine, Hüttmann, Andreas, Reinhardt, Hans Christian, von Tresckow, Bastian, Herrmann, Ken, Dührsen, Ulrich, Schäfers, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712103/
https://www.ncbi.nlm.nih.gov/pubmed/36241697
http://dx.doi.org/10.1038/s41375-022-01713-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712103/
https://www.ncbi.nlm.nih.gov/pubmed/36241697
http://dx.doi.org/10.1038/s41375-022-01713-y

Ejemplares similares